Company profile
Theralink Technologies, Inc.
OTC: THER · Healthcare · Biotechnology
#916 of 1,418 Healthcare companies by revenue52nd-percentile growth
EA Score
——FH —DQ 27GM —SS 44
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, listing tenure · ↓ growth stability, return on assets
Methodology →Revenue TTM
$753.9k
Rev growth YoY (TTM)
+32.8%
Net income (FY)
-$30.9M
Employees
16
as of 2026-08-26
Market cap
$615.1k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$606.8k$606.8k2023
Net income-$30.9M-$30.9M2023
Operating income-$9.0M-$9.0M2023
Total assets$2.8M$2.8M2023
Liabilities$41.0M$41.0M2023
Equity-$38.1M-$38.1M2023
Revenue trend
FY2012 – FY2023 · USD
FY12
FY15
FY15
FY15
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Theralink Technologies, Inc.’s revenue?
Theralink Technologies, Inc. booked $606.8k in FY2023 revenue, growing 6.8% year over year — about the middle of the pack among Healthcare companies we track, at a -5093.6% net margin.
Peers · Healthcare
CEN Biotech, Inc.——Co-Diagnostics, Inc.33DNovelStem International Corp.37DVaccinex, Inc.——CBD of Denver, Inc.35DCardiff Oncology, Inc.53DNeighbors
Jefferson →Key facts
CEOMichael I. Ruxin
SectorHealthcare
IndustryBiotechnology
HeadquartersGolden, CO
ExchangeOTC: THER
Employees16
IPO date2010-04-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.